5 Amendments of Stefano MAULLU related to 2016/2057(INI)
Amendment 33 #
Draft opinion
Paragraph 1
Paragraph 1
1. Highlights the fact that the WTO TRIPS Agreement provides flexibilities to patent rights, such as compulsory licensing, which have proved to be a major tool in bringing prices to reasonable levelsshould be used only in exceptional circumstances , when all other alternatives have been exhausted;
Amendment 44 #
Draft opinion
Paragraph 2
Paragraph 2
2. Considers that exclusive protection periods granted to pharmaceuticals through patents or other mechanisms hinder competition, lead to high prices and negatively impact access to needed medicinesRecognises the key contribution of IP-intensive industries such as the pharmaceutical sector in enhancing the competitiveness of European economy and delivering growth and high-quality jobs in the EU;
Amendment 56 #
Draft opinion
Paragraph 3
Paragraph 3
3. Recalls that the Pharmaceutical Sector Inquiry Report adopted by the Commission in 2009 showed that manufacturers of medicinidentified the numerous regulatory obstacles thave developed abusive strategies in connection with patent claims in order to hinder market entry of generic medicines, which should be avoidedt need to be addressed to achieve more efficient innovative and off-patent pharmaceutical markets;
Amendment 61 #
Draft opinion
Paragraph 4
Paragraph 4
4. Calls on the Commission to undertake a critical review of the impact of intellectual-property-related incentives on biomedical innovation, to explore credible and efficient alternatives to monopoliepatents for the financing of medical R&D and to evaluate the functioning of the applicable limitations to patent allocations;
Amendment 70 #
Draft opinion
Paragraph 5
Paragraph 5
5. Calls on the European Patent Office (EPO) and the Member States to continue to grant patents on health products that strictly fulfil the patentability requirements of novelty, inventive step and industrial applicability as enshrined in the European Patent Convention;